Table 1.
Clinical and demographic characteristics
| Data/subgroups | No CHT (n = 14) | CHT (n = 14) | p Valuea |
|---|---|---|---|
| Age (years) |
52 ± 10 |
52 ± 10 |
1.00 |
| Gender (M/F) |
11/3 |
11/3 |
1.00 |
| Education (years) |
14 ± 5 |
14 ± 5 |
0.96 |
| Type (HL/NHL) |
2/12 |
2/12 |
1.00 |
| Age at onset (years) |
52 ± 10 |
51 ± 9 |
0.96 |
| PET localization outside brain (yes/no) |
11/3 |
4/10 |
0.01 |
| Lymphoma symptoms (yes/no) |
5/9 |
5/9 |
1.00 |
| Cycles number (n) |
- |
6 ± 3 |
- |
| Post-CHT time (months) |
- |
7 ± 9 |
- |
| First-line treatmentb (n) |
- |
9 |
- |
| Second-line treatment (n) |
- |
5 |
- |
| Immunochemotherapy (n) |
- |
10 (7/3)c |
- |
| MMSE/30 |
28.4 ± 1.3 |
28.1 ± 1.1 |
0.63 |
| HADS depression/21 |
4 ± 3 |
4 ± 3 |
0.86 |
| HADS anxiety/21 |
6 ±3 |
4 ±3 |
0.17 |
| MADRS/50 |
9 ± 6 |
8 ± 7 |
0.68 |
| DT/10 | 3 ±2 | 2 ±2 | 0.28 |
CHT, chemotherapy; F, females; HL, Hodgkin's lymphoma; M, males; NHL, non-Hodgkin's lymphoma. a Significance p, for two independent sample t test or p Chi-square test. bFirst-line treatment, ABVD (hydroxydaunorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine) or CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine (Oncovin), prednisone or prednisolone). cImmunochemotherapy, treatment plus immunotherapy (rituximab). Values represent, when not otherwise specified, mean ± standard deviation.